3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Skin Care -

Aldara slows return of cold sores

Skin CareSep 14, 05

Aldara cream can delay the return of cold sores, but it can cause severe inflammation, according to a report in the journal Clinical Infectious Diseases.

Studies in guinea pigs found the cream reduced sore formation during and after treatment, Dr. David I. Bernstein of the Cincinnati Children’s Hospital Medical Center and colleagues note. He and his colleagues hypothesized that Aldara (generic name, imiquimod) could boost the body’s defenses against the herpes virus, which causes cold sores, and delay the return of the lesions.

To investigate, they compared Aldara with an inactive “vehicle” cream in 47 patients with recurrent cold sores. Study participants applied the cream within 48 hours after the reappearance of a lesion and then again a few days later.

Subjects who used Aldara reported more severe redness, swelling, scabbing, pain and burning, in some cases occurring after the application of the first dose. Treatment was halted early due to severe side effects in five patients treated with Aldara.

However, as noted, lesions returned more slowly after being treated with Aldara compared with the vehicle cream. With Aldara, it typically took around 100 days for lesions to return, whereas with the vehicle cream, it was just 50 days.

During the six-month follow up period, 73 percent of patients on Aldara reported a return of their lesions, compared with 94 percent of patients using vehicle cream.

Local side effects in this study were more severe than those observed when the drug was used for genital herpes, the researchers note, although the overall rate of side effects was similar.

“Alternative dosing regimens or lower concentrations might reduce the risk of severe local adverse effect, but would need to be adequately studied,” the researchers conclude.

SOURCE: Clinical Infectious Diseases, September 15, 2005.

Print Version
comments powered by Disqus

  Gene may open door for improved keloid, scar treatment
  Men, boomers fuel growth in spa industry
  Stick-on tattoos go electric
  Cell binding discovery brings hope to those with skin and heart problems
  Features of the metabolic syndrome common in persons with psoriasis
  Artificial “skin” materials can sense pressure
  2010 “Suntelligence: How Sun Smart is Your City?” Fact Sheet
  Association Discovered Between Eczema in Early Childhood and Psychological Problems
  Psoriasis treatment may up cancer risk
  Severe Cases of Psoriasis Can be Associated with Other Serious Medical Conditions
  Investigational study of ustekinumab in the treatment of psoriatic arthritis published
  TNF-blocker therapy for RA may trigger psoriasis


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site